I remember September 11th, 2001, as if it were yesterday. I was working as a relief pharmacist in Morgan City, Alabama, when my wife called to tell me there had been an airplane crash in New York. In these pre-smartphone days, news traveled a little bit slower and the pharmacy I was working in did not have a television so we made do with a radio. I remember the confusion—there were some early reports about additional planes headed for landmarks across Washington, DC.

WASHINGTON, DC — Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, executive vice president and CEO of APhA, commended the Federal Trade Commission’s (FTC) action today against alleged practices by large vertically integrated pharmacy benefit managers (PBMs) “for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs, impaired patients’ access to lower list price products, and shifted the cost of high insulin list prices to vulnerable patients.”

New research published in JAMA finds a deep concentration of PBM services are evident across all three payer markets, especially Medicare Part D.

According to the tenth installment of the Pharmacy Workplace and Well-being Reporting (PWWR) series, community pharmacists continue to suffer discrimination, harassment, and aggression on the job, but more are pushing back with legal action.